Clinical Trials Logo

Clinical Trial Summary

This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.


Clinical Trial Description

This is an open-label single-arm trial to evaluate the efficacy of Rifaximin in patients with active microscopic colitis (MC). 10 subjects will be asked to take 500mg Rifaximin three times per day for 4 weeks. The primary endpoints will be histologic response and clinical remission (less than 3 stools per day and less than 1 watery stool per day within the prior 7 days. The secondary endpoint will be change of the MC Disease Activity Index (MCDAI). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04043897
Study type Interventional
Source NorthShore University HealthSystem
Contact Daniel Amusin, BS
Phone 847-570-3558
Email damusin@northshore.org
Status Recruiting
Phase Phase 2
Start date June 29, 2018
Completion date December 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05998174 - Faecal Microbiota Transplantation for Microscopic Colitis Early Phase 1
Recruiting NCT05058131 - Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre N/A
Completed NCT02303132 - Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis N/A
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Recruiting NCT06031064 - External Validation of a Microscopic Colitis Clinical Scoring System in Patients With Chronic Watery Diarrhoea
Recruiting NCT06172647 - Mucosa Adherent Intestinal Microbiome in Microscopic Colitis and Colorectal Cancer
Recruiting NCT03477032 - FMT in Inflammatory Bowel Disease
Completed NCT03275467 - Faecal Microbiota Transplantation in Patients With Microscopic Colitis N/A
Completed NCT01928667 - Case-Control Study to Identify Risk Factors for Microscopic Colitis N/A
Completed NCT00180050 - Budesonide Treatment for Lymphocytic Colitis Phase 3
Not yet recruiting NCT05915104 - Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Phase 2
Completed NCT00952952 - Trial of Mesalamine for the Treatment of Active Microscopic Colitis Phase 2/Phase 3